Ignite Creation Date:
2024-05-06 @ 5:51 PM
Last Modification Date:
2024-10-26 @ 2:37 PM
Study NCT ID:
NCT05456802
Status:
COMPLETED
Last Update Posted:
2023-12-05
First Post:
2022-06-30
Brief Title:
Effect of Acute Cardiovascular Disease on Microbiome
Sponsor:
University Hospital Essen
Organization:
University Hospital Essen
Study Overview
Official Title:
The Influence of a Symptomatic Coronary Artery and Peripheral Arterial Disease on the Oral-enteral Microbiome and Downstream Microbiome-dependent Metabolites
Status:
COMPLETED
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MIAMI
Brief Summary:
Atherosclerotic diseases such as coronary artery disease CAD and peripheral arterial disease PAD are the leading cause of morbidity and mortality in the industrialized world
An interaction between the development of atherosclerotic diseases and the oral and enteral microbiome composition has already been demonstrated in the past The microbiome is a double-edged sword which can convey protective and detrimental cardiovascular effects While it can promote the development of atherosclerosis through the production of atherogenic metabolites such as trimethylamine N-oxide TMAO it can also generate a protective effect through the production of metabolites such as short chain fatty acids SCFA Preliminary data suggest that atherosclerotic disease itself can induce a dysbiosis of the microbiome
Aim of this study is to determine the differences in coronary artery disease and peripheral arterial disease on the oral-enteral microbiome axis and downstream microbiome-dependent metabolites
An interaction between the development of atherosclerotic diseases and the oral and enteral microbiome composition has already been demonstrated in the past The microbiome is a double-edged sword which can convey protective and detrimental cardiovascular effects While it can promote the development of atherosclerosis through the production of atherogenic metabolites such as trimethylamine N-oxide TMAO it can also generate a protective effect through the production of metabolites such as short chain fatty acids SCFA Preliminary data suggest that atherosclerotic disease itself can induce a dysbiosis of the microbiome
Aim of this study is to determine the differences in coronary artery disease and peripheral arterial disease on the oral-enteral microbiome axis and downstream microbiome-dependent metabolites
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None